Extraordinary meeting of the Pharmacovigilance Risk Assessment Committee (PRAC): 18 March 2021
Location: Virtual meeting
This extraordinary meeting is organised in the context of the evaluation of a safety signal with Vaxzevria (previously COVID-19 Vaccine AstraZeneca) relating to cases of thromboembolic events.
The aim of the meeting is to conclude the evaluation of the signal based on the information gathered and make any necessary recommendations for further action.
The Pharmacovigilance Risk Assessment Committee (PRAC) is the European Medicines Agency's (EMA) committee responsible for assessing and monitoring the safety of human medicines.